Articles

Life Technologies might be on the market

Whether it is seeking a buyer, evaluating an acquisition offer or just looking to figure out how to best reconfigure its operations is unclear, but Life’s hiring of strategic advisors recently has tongues wagging mostly about a potential buyout
Written byJeffrey Bouley
| 2 min read

CARLSBAD, Calif.—Life, as they often say, is aboutchange. As it turns out, change may very well be in the works for Life, LifeTechnologies Corp., that is—possibly a change in ownership, based on recent actions bythe company.

Specifically, Life reported Jan. 18 that it hadretained Deutsche Bank AG and Moelis & Co. "to assist in its annual strategicreview," though the company also made a point of noting that "The board ofdirectors has not decided on any specific course of action."

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.